| __timestamp | BioCryst Pharmaceuticals, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 15746000 |
| Thursday, January 1, 2015 | 13047000 | 13392000 |
| Friday, January 1, 2016 | 11253000 | 9290000 |
| Sunday, January 1, 2017 | 13933000 | 7672000 |
| Monday, January 1, 2018 | 29514000 | 15293000 |
| Tuesday, January 1, 2019 | 37121000 | 22648000 |
| Wednesday, January 1, 2020 | 67929000 | 21864000 |
| Friday, January 1, 2021 | 118818000 | 37318000 |
| Saturday, January 1, 2022 | 159371000 | 48130000 |
| Sunday, January 1, 2023 | 213894000 | 108146000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, BioCryst Pharmaceuticals, Inc. and Madrigal Pharmaceuticals, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, BioCryst's SG&A expenses surged by nearly 280%, peaking in 2023. In contrast, Madrigal's expenses grew by approximately 590% during the same period, reflecting a more aggressive expansion strategy.
BioCryst's expenses remained relatively stable until 2018, after which they escalated, indicating a strategic shift. Meanwhile, Madrigal maintained a more consistent growth trajectory, with a notable spike in 2023. This data suggests that while both companies are expanding, their approaches to managing operational costs differ significantly. Investors and industry analysts should consider these trends when evaluating the companies' long-term sustainability and growth potential.
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?